
Wooting's 80HE Feels Like the Pinnacle of Hall Effect Keyboards
Later, when it debuted its Lekker Hall effect switch in the Wooting Two, it was one of the first companies to utilize the technology for gaming. Things ramped up in 2020 with the release of the Wooting 60HE: Wooting was taking preorders months in advance, the keyboard was reselling with massive markups, and Hall effect completely overshadowed optical switches as the next big thing.
Now, Hall effect keyboards are a dime a dozen. It kicked off an arms race, and Wooting's 60HE fell behind. But with the new Wooting 80HE, the company returned to the tenkeyless (TKL) layout of its first keyboard and made a keyboard that's not only competitive but impressive. The 80HE has every feature I want in a Hall effect keyboard, without any of the mistakes I commonly see. It's robust, reliable, and easy to repair.
The 80HE has two versions, one with a plastic case and the other with a zinc alloy. The plastic version retails for $200 and comes in opaque black or transparent gray. The zinc alloy model costs $290 and includes a carrying case. It comes in black or white. You can also get the keyboard in ANSI, ISO, and JIS layouts. I tested the zinc alloy case in black with a standard ANSI layout. Fantastic Functionality
Photograph: Henri Robbins
For nearly every Hall effect keyboard I've reviewed, software has been a sore spot. They've been buggy, awkward, poorly designed, filled with advertisements, or just plain unintuitive. Even the best software I've tested, from Keychron, has minor issues with connectivity and setting functions.
This is where Wooting stands out. Its in-house app, Wootility, is great. It's a simple, lightweight utility that provides extensive adjustments and customizations. It's available both in-browser and as a downloadable executable, meaning you can access it anywhere and use it offline. More than that, every part of its design makes sense: The application is organized, easy to use, intuitive, and explains every setting. Plus, during my entire time using the browser version, I never ran into connectivity issues—the minute I hit 'enter' for the URL, it recognized the keyboard. This isn't the case for most in-browser keyboard utilities, which don't always want to connect.
Even niche features like gamepad emulation worked flawlessly. I replicated the analog inputs of an Xbox controller's stick and triggers without any hiccups or confusion, adjusting the settings on the fly and still maintaining keyboard inputs for unmapped keys. I even put down a half-decent lap time in Art of Rally after a bit of practice (and a few crashes).

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner
The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneurs The founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapies Committee representatives presented the award and the EUR 100,000 cash prize on Thursday, July 3, 2025 Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year's winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech's founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide. 'On behalf of the award committee and this year's expert jury panel, we would like to congratulate Isabella Attinger-Toller, Dragan Grabulovski and Philipp Spycher. Together with the expert jury, we selected the founders of Araris Biotech as winners based on their combined leadership, entrepreneurial expertise and scientific excellence. Following the successful acquisition of Araris by Taiho Pharmaceuticals, we believe this award further recognizes the founding team's continued growth and positive trajectory ahead. This trio has impressively demonstrated how a new idea, a clear focus on translation and entrepreneurial boldness can come together to launch a new generation of targeted cancer therapies,' said Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., in a joint statement. 'It was a special privilege for us to engage with such a diverse, forward-looking group of start-ups from the DACH region. Learning more about the finalists and their impressive achievements made the final decision anything but easy.' The group of finalists selected in May comprised three companies: Araris Biotech, NovaGo Therapeutics and TOLREMO therapeutics, whose founders exemplify the entrepreneurial potential and scientific diversity that characterize the life sciences sector in the DACH region. They include an impressive variety of disciplines — spanning targeted cancer therapies, regenerative neuroscience and cancer drug resistance. Following the presentation of their entrepreneurial and scientific achievements to an expert jury, Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., were announced today as the winning team and will receive a joint cash prize of EUR 100,000. "We feel very honored to have our vision and achievements recognized by the Strüngmann Award. As the founding team, we have always believed in the potential of our new technology and the value it may hold for patients. This award, in addition to the acquisition by Taiho Pharmaceuticals, is a validation of our commitment, shared journey and the hard work that has enabled our success story," said Dragan Grabulovski, Ph.D., CEO of Araris Biotech, on behalf of the founding team. The Araris Biotech founders, the experienced biotech entrepreneur Dragan Grabulovski, Ph.D., (CEO), the visionary scientist Philipp Spycher, Ph.D., (CSO) and the outstanding translational scientist Isabella Attinger-Toller, Ph.D., (CTO), can look back on one of the most successful Swiss biotech startups to be established in recent years. Spun out of the Paul Scherrer Institute (part of ETH domain) in 2019, the team developed a novel ADC linker-payload technology (AraLinQ™) that enables one-step payload attachment to off-the-shelf antibodies, without the need for prior antibody engineering. This innovative approach not only opens new possibilities in oncology, but also has potential for applications in other therapeutic areas. In only a few years, the Araris team raised over CHF 40 million, formed a strategic partnership with Chugai (Roche) and Johnson & Johnson, and achieved a landmark acquisition by Taiho Pharmaceutical in March 2025 for up to USD $1.14 billion. Through these achievements, the three winners exemplify the potential within the DACH region to successfully translate scientific excellence into global innovation. About the Strüngmann AwardThe award was established in 2024 to recognize outstanding entrepreneurs realizing revolutionary ideas in the DACH life science sector. The goal is to reward exceptional achievements with a prestigious prize and to further the development of the next generation of leaders in this space. The award was named to honor twin brothers Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., who are among the important entrepreneurs, visionaries and investors in the life science sector. As the founders of Hexal, they achieved extraordinary entrepreneurial success and as investors, they have continued to repeat that success for more than 20 years by building and developing leading companies across the industry, including Mainz-based BioNTech. Learn more at About Araris Biotech AGAraris Biotech is a leading biotech company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris' vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy. By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of smart missiles that deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance. Araris is a wholly owned subsidiary of Taiho Pharmaceutical following its acquisition in March 2025. For more information about our science and pipeline, please visit Media ContactTrophic CommunicationsStephanie May, Ph.D. and Anja HeuerPhone: +49 (0) 171 185 56 82Email: athos@ Attachment Strüngmann Award 2025 Goes To Araris BiotechSign in to access your portfolio
Yahoo
an hour ago
- Yahoo
SailPoint Recognized as Leader in Cloud Infrastructure Entitlement Management by KuppingerCole
SailPoint Inc. (NASDAQ:SAIL) is one of the best new stocks to buy now. On June 24, SailPoint announced that it had been recognized as an Overall Leader, Product Leader, Innovation Leader, and Market Leader in the 2025 KuppingerCole Leadership Compass for Cloud Infrastructure Entitlement Management/CIEM. The report evaluates CIEM vendors based on innovation, usability, and market presence. SailPoint's performance across these categories shows the effectiveness of its enterprise-grade approach to entitlement governance within complex multi-cloud environments. A cybersecurity expert monitoring the security of the company's assets, emphasizing the importance of data protection. The increasing complexity of managing and securing entitlements across multi-cloud setups has made CIEM solutions indispensable for organizations. SailPoint CIEM caters to the needs of complex enterprises that operate in multi-cloud environments. SailPoint Inc. (NASDAQ:SAIL) delivers solutions to enable identity security for the enterprise in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. While we acknowledge the potential of SAIL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Consider 2 investment trusts and funds to target £160k from a £20k lump sum!
I believe these high-growth investment trusts and exchange-traded funds (ETFs) could be excellent wealth creators over the next decade. Here's why they're worth further research today. The technology sector is packed with investment potential. US chip-making giant Nvidia's rise to become the most expensive company in history (market cap: $3.92trn) on Thursday (3 July) underlines this point. But while megatrends like artificial intelligence (AI), robotics and cloud computing are tipped for stratospheric growth, knowing which companies to buy to capitalise on them can be difficult. BlackBerry and Yahoo! are just a couple of former giants that failed to keep up with technological shifts. Investment trusts like Polar Capital Technology Trust (LSE:PCT) help reduce this problem for us. This particular operation is invested in 98 different tech shares. These range from semiconductor manufacturers to software developers (like Microsoft), smartphone makers (such as Apple) and online retailers (like Amazon). It's critical to remember that many of the tech stocks it owns (such as Nvidia) command high valuations. As a result, the fund could fall sharply if market sentiment towards the sector begins to sour. But I think the long-term benefits of ownership outweigh this possibility. Since 2015, the trust has delivered an average annual return of 19.9%. One final thing: total the trust trades at a 9.2% discount to its net asset value (NAV) per share. European defence shares have (largely) performed extremely strongly since Russia's invasion of Ukraine just over three years ago. With rising defence spending since then, it seems as if the sector has further room to grow. The VanEck Defence UCITS ETF (LSE:DFNS) could be a a great fund to consider in this landscape. While there are uncertainties over future US defence spending, expenditure in Europe is expected to soar to pick up the slack and respond to perceptions of a rising global threats. Defence-related expenditure has risen by three-quarters since early 2022, according to analysts at Allianz. And they think spending will have to rise significantly if NATO members are to meet a target to spend 3.5% on core defence (such as weapons and manpower) by 2035. It projects, for instance, that Germany will have to spend an extra $64bn per year, Italy $47bn, France $45bn and the UK $41bn, relative to last year's levels. This bodes well for the 29 defence contractors that this VanEck ETF owns. These include US industry giants like Palantir and RTX, alongside Europe-based companies like Thales and Leonardo. As the fund was only launched in March 2023, it's not possible to compare any sort of long-term returns as I can with Polar Capital. But since 2023, it's provided an average annual return of 22% with the total return in that period being 57.3%. Past performance isn't a reliable guide to the future. But I'm optimistic it can continue delivering strong returns in the developing geopolitical landscape. That's despite ongoing challenges in defence, like supply chain disruptions and rising costs. If VanEck's fund can replicate recent returns, and Polar Capital can maintain its performance since 2015, a £10,000 lump sum invested equally across them could turn into £160,384 within 10 years. Things could go wrong too and investors could lose money. But I still think both are worth consideration now. The post Consider 2 investment trusts and funds to target £160k from a £20k lump sum! appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Amazon, Apple, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data